#genzyme

Global Mononucleosis Diagnostic Market Synopsis:

Mononucleosis Diagnostic Market research report gives analysis and data according to categories such as Market segments, regions, types, technology, end-user, applications and so on. The report offers current industry data and upcoming trends of the industry, allowing the recognition of the products and end users boosting revenue growth and profitability. Analysis and discussion of important industry trends, Market size, and Market share estimates are revealed in the report. The market report is a comprehensive analysis on the study of Healthcare industry. Global Mononucleosis Diagnostic report also supports to secure economies in the distribution of products and find out the best way of approaching the potential.

Moreover, the persuasive Mononucleosis Diagnostic Market analysis document is structured with different graphical representations like graphs, charts, figures and diagrams with the specific arrangement of vital outlines, strategic diagrams, and illustrative figures based on reliable information to depict a correct picture of value judgement and income graphs. Market research covered in this advertising report helps the management of a firm in planning by providing accurate and up- to-date information about the consumer’s demands, their changing tastes, attitudes, preferences, and buying intentions etc. With the data covered in the first class Mononucleosis Diagnostic report, Marketing of goods can be made efficient and economical which leads to elimination of all type of wastage.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mononucleosis-diagnostic-market .

The Global Mononucleosis Diagnostic Market is expected to grow with a CAGR of 5.0% in the forecast period of 2020 to 2027.

According to the market report analysis, Mononucleosis is a type of infectious disease caused because of the Epstein-Barr virus (EBV), with infection typically occurring in teenagers. The virus can spread through the saliva and if anyone gets EBV, the chances are probably very high that they become immune to mononucleosis for the rest of their life.

Some of most important key factors driving the growth of the Global Mononucleosis Diagnostic Market are rise in the adolescent population across the world, technological advancements leading to faster diagnosis and rising incidence of Infectious Mononucleosis (IM).

The major players covered in the Mononucleosis Diagnostic Market report are Abbott, DAIICHI SANKYO COMPANY, LIMITED., Weizmann Institute of Science., Biotest AG., Bio-Rad Laboratories, Inc., Genzyme Corporation., F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., BD, DiaSorin Molecular LLC. , Beckman Coulter, Inc., bioMérieux SA, Siemens, Sekisui Diagnostics Quidel Corporation. among other domestic and global players.

Regional analysis, APAC dominates the mononucleosis diagnostic market due to the rising adolescent population and rising incidence of infectious mononucleosis (IM) in the region.

COLLECTOR Issue Debut Album ‘Liberation’s Fall’; Features Guests Chris Broderick (Act Of Defiance), Vicky Psarakis (The Agonist), Warrell Dane (Nevermore, Sanctuary) & More

(By Pat ‘Riot’ Whitaker, Senior Writer/Journalist, RiffRelevant.com)

There is powerful new blood in the world of progressive, technical metal… and it arrives in the form of Boston’s COLLECTOR. (more…)

In a first, government provides Rs one large integer for treating rare disorders

The authorities on weekday told the state supreme court that it’s provided `1 large integer to Mrs. Gandhi Institute of kid Health (IGICH) to begin associate degree catalyst replacement medical aid for twenty-six youngsters full of Lysosomal storage disorders (LSD). The government’s call comes when the state supreme court passed a judgment during this regard last June. this is often a historic…

The biotech IPO space has been sparse over the last few months, as a number of high profile offerings have delayed or fallen through on weak capital flow expectations. One that did go through, however, and (arguably) successfully, was that of Voyager Therapeutics, Inc. (NASDAQ:VYGR). The company launched to NASDAQ with an $80.5 million draw ($72.7 million net), and across the subsequent four weeks gained 70% to log 2015 highs of a little over $30 a share.

Click Here For More Market Exclusive Updates & Analysis

At last close, however, Voyager stock traded at just $10.5 a share, 65% off highs. There haven’t really been any major fundamental updates to drive this decline – a few reiterated ratings by analysts, a financial report with no real surprises and, most recently, the promotion of its senior vice president of finance and business development, to chief financial officer – suggesting the decline comes on the back of wider biotech weakness rather than a sentiment shift specific to the company.

In turn, it flags the company as a potential discount entry. If market perception drove the company to highs on the potential of its pipeline, then that valuation could well be more accurate than today’s. Of course, and as always, there are some stumbling blocks to regaining that valuation. Let’s have a look at what the company is developing in an attempt to determine whether the current price is justified.

The company’s pipeline contains five candidates, each with a separate CNS target. Only one, however, is anywhere near commercialization, and even that is a good few years from an NDA. With this in mind, the assumption is that the company’s valuation is rooted in the potential of this one candidate – VY-AADCO1 – a Parkinson’s disease drug. We’ve discussed the Parkinson’s space a few times before on Market Exclusive, but if you’ve missed these discussions, they all boil down to one thing: Parkinson’s is notoriously difficult to treat. More than 90% of Parkinson’s drugs fail to demonstrate efficacy in phase III, and they can be very costly to develop due to the comparative lack of scientific understanding we currently have about the root cause, and progression, of the disease. Having said this, it’s one of those “holy grail” areas. A company that successfully develops a cure has a fast track to blockbuster status, which is why so many companies allocate so high a level of resources to the space.

The company has developed what it calls AAV technology, which is a way to deliver a transgene into a patients CNS. Transgene is just a term for the introduction of a gene into a patient – in this instance it’s achieved using a viral vector. With VY-AADCO1, the gene that codes for the production of an enzyme called AADC is introduced. Parkinson’s patients gradually lose the ability to produce AADC, which is essential in converting what’s called levodopa to dopamine – and the lack of dopamine causes the symptoms associated with disease progression.

Similar treatments are available generically in pill form, but their efficacy reduces the longer a patient takes the drug. By introducing AADC producing genes, Voyager is hoping its treatment will overcome this efficacy degradation. The drug is currently in a phase Ib, so we’ve not got much to go on from a data perspective, but topline is expected during the second half of this year. If we get proof of concept from the trial, it could quickly add some upside to Voyager’s market cap.

There are downsides, however. The treatment requires surgical administration, and many Parkinson’s patients are elderly and – as such – risky candidates for surgical procedures. This will play into the risk benefit analysis performed by the FDA if the drug reaches that stage. Additionally, the company is hemorrhaging money. It netted a $22 million loss for the nine months to September last year, and these losses will increase as the development timeline progresses.

On the other side of the coin, Sanofi (NYSE:SNY), through its subsidiary Genzyme, is funding a large portion of the trial, having announced what what could amount to an $845 million deal this time last year.

So what’s the verdict? Well, it’s a risky allocation – that’s a sure thing. Having said this, it’s got the backing of a biotech behemoth and a pipeline of new approaches to CNS diseases – a very lucrative market if any reach commercialization. Topline will be pivotal in forming a bias. If we see efficacy, expect some upside and a reversal in sentiment to bullish. If not, the company could be looking at a considerable hit.

you need to know whether you are a potential candidate and if the drug will be reimbursed.

+

[20150413] 庞贝氏患儿面临治疗两难 要用1亿元换30年生命？

3月13日，青岛庞贝氏患儿果果在热心网友和青岛媒体的帮助下，筹集到了一百多万元药费，并联系到了庞贝氏病的药物研发者——台湾中央研究院生物医学科学研究所所长陈垣崇博士，获得了一次赴台湾自费用药的机会。

↑↑↑

[20150426] 王建煊建議郭台銘 無黨籍身分選總統

Medtronic, Genzyme Lead U.S. Orthopedic Biomaterials Market Is Projected to Reach $3.88 Billion by 2021

Vancouver, BC (PRWEB) December 04, 2014

According to a report by iData Research, the leading global authority in medical device market research, the U.S. orthopedic biomaterials market is expected to grow to nearly $ 3.88 billion by 2021. Hyaluronic acid viscosupplementation used in the treatment of osteoarthritis to delay total knee replacement, accounts for the majority of the market growth…

Things just got real for MSontheRoad.